Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 13/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | UBE2M | P61081 | 1/20 | 0.38 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18342724 | 0.90 | IDO1 (0.48) | IDO1NPC1KMT2ARAB9AUBE2M | |
| SCHEMBL18342969 | 0.85 | IDO1 (0.46) | IDO1NPC1KMT2AUBE2MDCUN1D1 | |
| SCHEMBL18342976 | 0.83 | IDO1 (0.44) | IDO1NPC1KMT2ARAB9AUBE2M | |
| SCHEMBL18342963 | 0.83 | IDO1 (0.43) | IDO1NPC1KMT2AUBE2MDCUN1D1 | |
| SCHEMBL20620246 | 0.81 | IDO1 (0.51) | IDO1KMT2AUBE2MDCUN1D1ALDH1A1 | |
| SCHEMBL19232077 | 0.80 | IDO1 (0.53) | IDO1KMT2AUBE2MDCUN1D1 | |
| SCHEMBL18342819 | 0.80 | IDO1 (0.51) | IDO1KMT2AUBE2MDCUN1D1ALDH1A1 | |
| SCHEMBL19987571 | 0.79 | IDO1 (0.51) | IDO1NPC1KMT2ARAB9AUBE2M | |
| SCHEMBL18342751 | 0.79 | IDO1 (0.51) | IDO1KMT2AUBE2MDCUN1D1ALDH1A1 | |
| SCHEMBL18342907 | 0.78 | IDO1 (0.48) | IDO1NPC1KMT2ARAB9AUBE2M |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689331-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190002402-A1 | IDO INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-01-03 | — | — | US | disclosed |
| EP-3313824-A1 | IDO INHIBITORS | Bristol-Myers Squibb Company (US) | 2018-05-02 | — | — | EP | disclosed |
| WO-2016210414-A1 | IDO INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002402-A1 | IDO INHIBITORS | IDO1, IDO2, INMT | IDO1 1/4885NPC1 2825/4885KMT2A 461/4885 |
| US-10689331-B2 | IDO inhibitors | IDO1, IDO2, INMT | IDO1 1/4885NPC1 2825/4885KMT2A 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.